GW 405833| CAS#180002-83-9 | CB2 Receptor Agonist

MedKoo Cat#: 525422 | Name: GW405833

Description:

WARNING: This product is for research use only, not for human or veterinary use.

GW405833 (also known as L-768,242) is a synthetic, selective partial agonist of the cannabinoid receptor subtype CB₂, exhibiting an EC₅₀ of approximately 0.65 nM and demonstrating over 1,200-fold selectivity for CB₂ over CB₁ receptors . Preclinical studies have shown that GW405833 effectively suppresses inflammatory and neuropathic pain in rodent models without eliciting the central nervous system side effects commonly associated with CB₁ receptor activation . Interestingly, recent in vitro findings suggest that GW405833 may also function as a noncompetitive antagonist at CB₁ receptors, indicating a more complex pharmacological profile than initially understood

Chemical Structure

GW405833

CAS#180002-83-9

Theoretical Analysis

MedKoo Cat#: 525422

Name: GW405833

CAS#: 180002-83-9

Chemical Formula: C23H24Cl2N2O3

Exact Mass: 446.1164

Molecular Weight: 447.36

Elemental Analysis: Elemental Analysis: C, 61.75; H, 5.41; Cl, 15.85; N, 6.26; O, 10.73

Price and Availability

Size	Price	Availability	Quantity
10mg	USD 350.00	2 Weeks
25mg	USD 650.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

L-768242; L768242; L 768242; GW-405833; GW405833; GW 405833;

IUPAC/Chemical Name

1-(2,3-Dichlorobenzoyl)-5-methoxy-2-methyl-3-(2-morpholinoethyl)-1H-indole

InChi Key

FSFZRNZSZYDVLI-UHFFFAOYSA-N

InChi Code

InChI=1S/C23H24Cl2N2O3/c1-15-17(8-9-26-10-12-30-13-11-26)19-14-16(29-2)6-7-21(19)27(15)23(28)18-4-3-5-20(24)22(18)25/h3-7,14H,8-13H2,1-2H3

SMILES Code

CC(N1C(C2=CC=CC(Cl)=C2Cl)=O)=C(CCN3CCOCC3)C4=C1C=CC(OC)=C4

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Certificate of Analysis

View CoA: current batch, Lot#C9M08C08

Safety Data Sheet (SDS)

View Safety Data Sheet (SDS)

Instruction

View handling instruction

Biological target:

A selective CB2 partial agonist.

In vitro activity:

To detect the function of CB2R agonist GW (GW405833) on the cytoactive Jurkat T lymphocytes, the relative cytoactive rates of the Jurkat T lymphocytes measured at different time points (from 3 to 24 h) were tested by CCK-8. With increasing concentrations of GW and extended time of treatment, the cytoactive rate of the T lymphocytes was significantly reduced. The overall trend of cell viability declined under the dose-dependent and time-dependent effect of GW (Fig. 4). Reference: Acta Pharmacol Sin. 2019 Nov;40(11):1404-1411. https://pubmed.ncbi.nlm.nih.gov/30918343/

In vivo activity:

Pre-treatment of rat with CB2 selective receptor agonist GW405833 decreases paw oedema, tissue inflammatory cell infiltration and increased MPO level, tissue lipid peroxidation, and serum TNF-α level. CB2 receptor activation also increases the tissue GSH level. Reference: Exp Ther Med. 2018 Dec;16(6):4900-4908. https://pubmed.ncbi.nlm.nih.gov/30542446/

	Solvent	mg/mL	mM
Solubility
	DMF	10.0	22.35
	DMF:PBS (pH 7.2) (1:4)	0.2	0.45
	DMSO	5.0	11.18
	Ethanol	0.3	0.67

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 447.36 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Huang ZB, Zheng YX, Li N, Cai SL, Huang Y, Wang J, Hu XW, Wang Y, Wu J, Fan XG. Protective effects of specific cannabinoid receptor 2 agonist GW405833 on concanavalin A-induced acute liver injury in mice. Acta Pharmacol Sin. 2019 Nov;40(11):1404-1411. doi: 10.1038/s41401-019-0213-0. Epub 2019 Mar 27. PMID: 30918343; PMCID: PMC6888824. 2. Parlar A, Arslan SO, Doğan MF, Çam SA, Yalçin A, Elibol E, Özer MK, Üçkardeş F, Kara H. The exogenous administration of CB2 specific agonist, GW405833, inhibits inflammation by reducing cytokine production and oxidative stress. Exp Ther Med. 2018 Dec;16(6):4900-4908. doi: 10.3892/etm.2018.6753. Epub 2018 Sep 18. PMID: 30542446; PMCID: PMC6257606. 3. Li AL, Carey LM, Mackie K, Hohmann AG. Cannabinoid CB2 Agonist GW405833 Suppresses Inflammatory and Neuropathic Pain through a CB1 Mechanism that is Independent of CB2 Receptors in Mice. J Pharmacol Exp Ther. 2017 Aug;362(2):296-305. doi: 10.1124/jpet.117.241901. Epub 2017 Jun 7. PMID: 28592614; PMCID: PMC5502377.

In vitro protocol:

In vivo protocol:

1. Parlar A, Arslan SO, Doğan MF, Çam SA, Yalçin A, Elibol E, Özer MK, Üçkardeş F, Kara H. The exogenous administration of CB2 specific agonist, GW405833, inhibits inflammation by reducing cytokine production and oxidative stress. Exp Ther Med. 2018 Dec;16(6):4900-4908. doi: 10.3892/etm.2018.6753. Epub 2018 Sep 18. PMID: 30542446; PMCID: PMC6257606. 2. Li AL, Carey LM, Mackie K, Hohmann AG. Cannabinoid CB2 Agonist GW405833 Suppresses Inflammatory and Neuropathic Pain through a CB1 Mechanism that is Independent of CB2 Receptors in Mice. J Pharmacol Exp Ther. 2017 Aug;362(2):296-305. doi: 10.1124/jpet.117.241901. Epub 2017 Jun 7. PMID: 28592614; PMCID: PMC5502377.

1: Inson I, Chutoe C, Kanjanapipak J, Lertsuwan K. Cannabinoid Receptor Type 2 Agonist, GW405833, Reduced the Impacts of MDA-MB-231 Breast Cancer Cells on Bone Cells. Cancer Med. 2025 Feb;14(4):e70709. doi: 10.1002/cam4.70709. PMID: 39980332; PMCID: PMC11842928. 2: Chutoe C, Inson I, Krobthong S, Phueakphud N, Khunluck T, Wongtrakoongate P, Charoenphandhu N, Lertsuwan K. Combinatorial effects of cannabinoid receptor 1 and 2 agonists on characteristics and proteomic alteration in MDA-MB-231 breast cancer cells. PLoS One. 2024 Nov 11;19(11):e0312851. doi: 10.1371/journal.pone.0312851. PMID: 39527598; PMCID: PMC11554208. 3: Duan J, Chen J, Lin Y, Lin SL, Wu J. Endocannabinoid Receptor 2 Function is Associated with Tumor-Associated Macrophage Accumulation and Increases in T Cell Number to Initiate a Potent Antitumor Response in a Syngeneic Murine Model of Glioblastoma. Cannabis Cannabinoid Res. 2024 Dec;9(6):1524-1536. doi: 10.1089/can.2024.0063. Epub 2024 Jun 18. PMID: 38888628; PMCID: PMC11685299. 4: Agnes JP, Dos Santos B, das Neves RN, Luciano VMM, Benvenutti L, Goldoni FC, Schran RG, Santin JR, Quintão NLM, Zanotto-Filho A. β-Caryophyllene Inhibits Oxaliplatin-Induced Peripheral Neuropathy in Mice: Role of Cannabinoid Type 2 Receptors, Oxidative Stress and Neuroinflammation. Antioxidants (Basel). 2023 Oct 22;12(10):1893. doi: 10.3390/antiox12101893. PMID: 37891972; PMCID: PMC10604080. 5: Haider A, Wang L, Gobbi L, Li Y, Chaudhary A, Zhou X, Chen J, Zhao C, Rong J, Xiao Z, Hou L, Elghazawy NH, Sippl W, Davenport AT, Daunais JB, Ahmed H, Crowe R, Honer M, Rominger A, Grether U, Liang SH, Ametamey SM. Evaluation of [18F]RoSMA-18-d6 as a CB2 PET Radioligand in Nonhuman Primates. ACS Chem Neurosci. 2023 Oct 18;14(20):3752-3760. doi: 10.1021/acschemneuro.3c00222. Epub 2023 Oct 3. PMID: 37788055. 6: Kallinen A, Mardon K, Lane S, Montgomery AP, Bhalla R, Stimson DHR, Ahamed M, Cowin GJ, Hibbs D, Werry EL, Fulton R, Connor M, Kassiou M. Synthesis and Preclinical Evaluation of Fluorinated 5-Azaindoles as CB2 PET Radioligands. ACS Chem Neurosci. 2023 Aug 16;14(16):2902-2921. doi: 10.1021/acschemneuro.3c00345. Epub 2023 Jul 27. PMID: 37499194. 7: Cai SL, Fan XG, Wu J, Wang Y, Hu XW, Pei SY, Zheng YX, Chen J, Huang Y, Li N, Huang ZB. CB2R agonist GW405833 alleviates acute liver failure in mice via inhibiting HIF-1α-mediated reprogramming of glycometabolism and macrophage proliferation. Acta Pharmacol Sin. 2023 Jul;44(7):1391-1403. doi: 10.1038/s41401-022-01037-8. Epub 2023 Jan 25. PMID: 36697976; PMCID: PMC10310807. 8: Parastouei K, Aarabi MH, Hamidi GA, Nasehi Z, Kabiri-Arani S, Jozi F, Shahaboddin ME. A CB2 Receptor Agonist Reduces the Production of Inflammatory Mediators and Improves Locomotor Activity in Experimental Autoimmune Encephalomyelitis. Rep Biochem Mol Biol. 2022 Apr;11(1):1-9. doi: 10.52547/rbmb.11.1.1. PMID: 35765518; PMCID: PMC9208571. 9: Khunluck T, Lertsuwan K, Chutoe C, Sooksawanwit S, Inson I, Teerapornpuntakit J, Tohtong R, Charoenphandhu N. Activation of cannabinoid receptors in breast cancer cells improves osteoblast viability in cancer-bone interaction model while reducing breast cancer cell survival and migration. Sci Rep. 2022 May 5;12(1):7398. doi: 10.1038/s41598-022-11116-9. PMID: 35513484; PMCID: PMC9072415. 10: Elgohary R, Abdelsalam RM, Abdel-Salam OM, Khattab MM, Salem NA, El-Khyat ZA, Morsy FA. Protective effect of cannabinoids on gastric mucosal lesions induced by water immersion restrain stress in rats. Iran J Basic Med Sci. 2021 Sep;24(9):1182-1189. doi: 10.22038/ijbms.2021.54338.12213. PMID: 35083004; PMCID: PMC8751742. 11: Li J, Ji J, Xu R, Li Z. Indole compounds with N-ethyl morpholine moieties as CB2 receptor agonists for anti-inflammatory management of pain: synthesis and biological evaluation. Medchemcomm. 2019 Sep 17;10(11):1935-1947. doi: 10.1039/c9md00173e. PMID: 32952995; PMCID: PMC7478157. 12: Spinelli F, Giampietro R, Stefanachi A, Riganti C, Kopecka J, Abatematteo FS, Leonetti F, Colabufo NA, Mangiatordi GF, Nicolotti O, Perrone MG, Brea J, Loza MI, Infantino V, Abate C, Contino M. Design and synthesis of fluorescent ligands for the detection of cannabinoid type 2 receptor (CB2R). Eur J Med Chem. 2020 Feb 15;188:112037. doi: 10.1016/j.ejmech.2020.112037. Epub 2020 Jan 7. PMID: 31954990. 13: Zhou H, Du R, Li G, Bai Z, Ma J, Mao C, Wang J, Gui H. Cannabinoid receptor 2 promotes the intracellular degradation of HMGB1 via the autophagy-lysosome pathway in macrophage. Int Immunopharmacol. 2020 Jan;78:106007. doi: 10.1016/j.intimp.2019.106007. Epub 2019 Dec 2. PMID: 31806570. 14: Huang ZB, Zheng YX, Li N, Cai SL, Huang Y, Wang J, Hu XW, Wang Y, Wu J, Fan XG. Protective effects of specific cannabinoid receptor 2 agonist GW405833 on concanavalin A-induced acute liver injury in mice. Acta Pharmacol Sin. 2019 Nov;40(11):1404-1411. doi: 10.1038/s41401-019-0213-0. Epub 2019 Mar 27. PMID: 30918343; PMCID: PMC6888824. 15: Parlar A, Arslan SO, Doğan MF, Çam SA, Yalçin A, Elibol E, Özer MK, Üçkardeş F, Kara H. The exogenous administration of CB2 specific agonist, GW405833, inhibits inflammation by reducing cytokine production and oxidative stress. Exp Ther Med. 2018 Dec;16(6):4900-4908. doi: 10.3892/etm.2018.6753. Epub 2018 Sep 18. PMID: 30542446; PMCID: PMC6257606. 16: Xia KK, Shen JX, Huang ZB, Song HM, Gao M, Chen DJ, Zhang SJ, Wu J. Heterogeneity of cannabinoid ligand-induced modulations in intracellular Ca2+ signals of mouse pancreatic acinar cells in vitro. Acta Pharmacol Sin. 2019 Mar;40(3):410-417. doi: 10.1038/s41401-018-0074-y. Epub 2018 Sep 10. PMID: 30202013; PMCID: PMC6460482. 17: Sánchez-Zavaleta R, Cortés H, Avalos-Fuentes JA, García U, Segovia Vila J, Erlij D, Florán B. Presynaptic cannabinoid CB2 receptors modulate [3 H]-Glutamate release at subthalamo-nigral terminals of the rat. Synapse. 2018 Nov;72(11):e22061. doi: 10.1002/syn.22061. Epub 2018 Aug 10. PMID: 30022523. 18: Li AL, Carey LM, Mackie K, Hohmann AG. Cannabinoid CB2 Agonist GW405833 Suppresses Inflammatory and Neuropathic Pain through a CB1 Mechanism that is Independent of CB2 Receptors in Mice. J Pharmacol Exp Ther. 2017 Aug;362(2):296-305. doi: 10.1124/jpet.117.241901. Epub 2017 Jun 7. PMID: 28592614; PMCID: PMC5502377. 19: Hillger JM, le Roy B, Wang Z, Mulder-Krieger T, Boomsma DI, Slagboom PE, Danen EHJ, IJzerman AP, Heitman LH. Phenotypic screening of cannabinoid receptor 2 ligands shows different sensitivity to genotype. Biochem Pharmacol. 2017 Apr 15;130:60-70. doi: 10.1016/j.bcp.2017.01.014. Epub 2017 Jan 31. PMID: 28159624. 20: Li MH, Suchland KL, Ingram SL. Compensatory Activation of Cannabinoid CB2 Receptor Inhibition of GABA Release in the Rostral Ventromedial Medulla in Inflammatory Pain. J Neurosci. 2017 Jan 18;37(3):626-636. doi: 10.1523/JNEUROSCI.1310-16.2016. PMID: 28100744; PMCID: PMC5242409.